General Newsroom Hero 1920x480 (4:1)
Our Work

Latham Advises Coherus in US$200 Million Offering of Convertible Senior Notes

April 15, 2020
A bi-coastal team represented the leading global biosimilar company in the transaction.

Coherus BioSciences, Inc. (“Coherus”) has announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.50% convertible senior subordinated notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The issuance and sale of the notes is scheduled to settle on April 17, 2020, subject to customary closing conditions. Coherus also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $30,000,000 principal amount of notes.

Latham & Watkins LLP represents Coherus BioSciences, Inc. in the transaction with a corporate team led by Bay Area partners Alan Mendelson and Benjamin Potter, and New York partners Greg Rodgers and Reza Mojtabaee-Zamani, with Bay Area associates Phillip Stoup, Meredith Peake and Casey Tong, and New York associates Andrew Blumenthal, Ryan Gold, Christopher Yu and Shawn Noh. Advice was also provided on tax matters by New York partner Elena Romanova, with New York associate Ronald Moore; and on finance matters by Bay Area partner Haim Zaltzman, with Bay Area associate Dan Van Fleet.

    Related Capabilities